Meloxicam

REFERENCES

• LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritic Rheum. (1998) 41:778–799.
   PubMed Web of Science ®Google Scholar
• HEDNER T, EVERTS B: The early clinical history of salicylates in rheumatology and pain. Clin. Rheumatol (1998) 17:17–25.
   PubMed Web of Science ®Google Scholar
• EVERTS B, WAHRBORG P, HEDNERT: Cox-2 specific inhibitors the emergence of a new class of analgesics and anti inflammatory drugs. Clin. Rheumatol (2000) 19:331–334.
   PubMed Web of Science ®Google Scholar
• SINGH G: Recent considerations in non steroidal anti-inflammatory drug gastropathy. Am. J. Med. (1998) 105:31S–38S.
   Google Scholar
• SINGH G, TRIADAFILOPOULOS G: Epidemiology of NSAID induced gastrointestinal complications. Rheumatol (1999) 26\(Suppl. 56):18–24.
   Google Scholar
• SMALLEY WE, GRIFFIN MR, FOUGHT RL et al.: Excess costs from gastrointestinal disease associated with n on steroidal anti-inflammatory drugs. j. Gen. Intern. Med. (1996) 11:461–469.
   PubMed Web of Science ®Google Scholar
• WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of non steroidal anti-inflammatory drugs. N Engl. Med. (1999) 340:1888–1899.
   PubMed Web of Science ®Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin like drugs. Nat. New Biol (1971) 231:232–235.
   PubMedGoogle Scholar
• VANE JR, BAKHLE YS, BOTTING RIVI:Cyclooxgenase 1 and 2. Ann. Rev Pharmacol Toxicol (1998) 38:97–120.
   PubMed Web of Science ®Google Scholar
• WARNER TD, GIULIANO F, VOJNOVIC I et al.: Nonsteroidal drug selectivities for cyclo-oxygenase 1 rather than cyclo-oxygenase 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Nati Acad. Sci. USA (1999) 96(13):7563–7568.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA, PATRONO C: The Coxibs, selective inhibitors of cyclooxgenase-2. N Engl. I Med. (2001) 345(6):433–442.
   PubMed Web of Science ®Google Scholar
• EVERTS B, WAHRBORG P, HEDNER T: COX 2 specific inhibitors the emergence of a new class of analgesic and anti-inflammatory drugs. Clin. Rheumatol (2000) 19:331–343.
   PubMed Web of Science ®Google Scholar
• RICHARDSON CE, EMERY P: New cyclo-oxygenase and cytokine inhibitors. (1995) 9(4):731–758.
   Google Scholar
• HECKEN A V, SCHWARTZ J I, DEPRE M et al.: Comparative Inhibitory activity of Rofecoxib, Meloxicam, diclofenac, Ibuprofen and Naproxen on COX2 versus COX1 in healthy volunteers. j. Clin. Pharmacol (2000) 40:1109–1120.
   PubMedGoogle Scholar
• DEQUEKER J, DEGNER F: Editorial. Inflamm. Res. (2001) 50\(Supp1.1):S3–S4.
   Google Scholar
• ENGELHARDT G: Pharmacology of Meloxicam, a new non-steroidal anti-inflammatory drug with improved safety profile through preferential inhibition of COX-2. Br: J. Rheumatol. (1996) 35\(Supp1.1):4–12.
   Google Scholar
• ENGELHARDT G, HOMMA D, SCHLEGEL K et al: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res. (1995) 44:423–433.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT G, BOGEL R, SCHNITZLER C et al.: Meloxicam: Influence on Arachidonic Acid Metabolism Part I in vitro findings. Biochem. Pharmacol (1996) 51:21–28.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT G, BOGEL R, SCHNITZLER C et al.: Meloxicam: Influence on Arachidonic acid metabolism, part II, in vivo findings. Biochem. Pharmacol (1996) 51:29–38.
   PubMed Web of Science ®Google Scholar
• PANARA M R, RENDA G, SCIULLI GS et al.: Dose dependent inhibition of platelet cyclooxgenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. I Pharmacol. Exp. Ther. (1999) 290:276–280.
   PubMedGoogle Scholar
• TORCK D, BUSCH U, HEINZEL G et al.: Clinical pharmacokinetics of meloxicam. Eur. Rheumatol Inflamm. (1996) 15:23–30.
   Google Scholar
• TORCK D, ROTH W, BUSCH U: A review of the clinical pharmacokinetics of meloxicam. Br. J. Rheumatol (1996) 35\(Suppl. 1):13–16.
   Google Scholar
• Meloxicam package insert.
   Google Scholar
• NARJES H, TORCK D, BUSCH U et al.: Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br. J. Pharmacol (1996) 41:135–139.
   Google Scholar
• DEGNER F, HEINZEL G, BUSCH U. Transynovial kinetics of meloxicam. Scand. Rheumatol (1994) (Suppl. 98). Abstract: 121.
   Google Scholar
• HUBNER G, SANDER 0, DEGNER F et al.: Lack of pharmacokinetic interaction of meloxicam with Methotrexate in patients with RA. J. Rheumatol (1997) 24(5):845–851.
   Google Scholar
• BUSCH U, HEINZEL G, NARJES H et al.: Investigation of interaction of meloxicam with cimetidine, Maalox or aspirin. j. Clin. Pharmacol (1996) 36(1):79–84.
   PubMed Web of Science ®Google Scholar
• MOLLER FO, SCHALL R, DEVAAL AC et al.: Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur.j Clin. Pharmacol. (1995) 48:247–251.
   PubMedGoogle Scholar
• TORCK D, HEINZEL G, LUIK G: Steady state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. Br. Clin. Pharmacol (2000) 50:197–204.
   PubMedGoogle Scholar
• TORCK D, SU CA, HEINZEL G et al.: Lack of interaction between meloxicam and warfarin in healthy volunteers. Ear: I Gin. Pharmacol (1997) 51(5): 421–425.
   Google Scholar
• BUSCH U, HEINZEL G, NARJES H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID), in man. Eur.j Clin. Pharmacol (1995) 48:269–272.
   Google Scholar
• YOCUM D, FLEISCHMANN R, DALGIN P et al.: Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch. Intern. Med. (2000) 160:2947–2954.
   PubMed Web of Science ®Google Scholar
• NIKAS SN, KITAS G, KARAMAOUNAS N et al: Meloxicam induced erythema multiforme. Am. j Med. (1999) 107(5):532–534.
   PubMedGoogle Scholar
• CARRABA M, PARESCE E, ANGELINI M, GALANTI A, MARINI MG, CIGARINI P: A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicenter study. Curr. Med. Res. Opin. (1995) 13:343–355.
   PubMedGoogle Scholar
• HOSIE J, DISTEL M, BLUHMKI E: Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclophenac sodium. Br: J. Rheumatol (1996) 35\(Supp1.1):39–43.
   Google Scholar
• LINDEN B, DISTEL M, BLUHMKI E: A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol. (1996) 35\(Supp1.1):35–38.
   Google Scholar
• HOSIE J, DISTEL M, BLUHMKI E: Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study. Cilia. Drug. Invest. (1997) 13:175–184.
   Web of Science ®Google Scholar
• GOEI THE HS, LUND B, DISTEL MR, BLUHMKI E: A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Ostenarthritis Cartilage (1997) 5:283–288.
   PubMed Web of Science ®Google Scholar
• LUND B, DISTEL M, BLUHMKI E: A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand. Rheumatol. (1998) 27:32–37.
   PubMed Web of Science ®Google Scholar
• HAWKEY C, KAHAN A, STEINBRUCK K et al.: Gastrointestinal tolerability of meloxicam compared to diclophenac in osteoarthritis patients. Br. j Rheumatol. (1998) 37:937–945.
   PubMedGoogle Scholar
• DEQUEKER J, HAWKEY C, KAHAN A et al.: Improvement in gastrointestinal tolerability of the selective cyclo-oxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large scale evaluation of COX-inhibiting therapies (Select) trial in osteoarthritis. Br. .1. Rheumatol. (1998) 37:946–951.
   Google Scholar
• VALAT JP, ACCARDO S, REGINSTER J-Y et al.: A comparison of the efficacy and tolerability of meloxicam and diclophenac in the treatment of patients with osteoarthritis of the lumbar spine. Inilamm. Res. (2001) 50\(Supp1.1):S30–S34.
   Google Scholar
• LEMMEL E-M, BOLTEN W, BURGOS-VARGAS R et al.: Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J. Rheumatol. (1997) 24:282–290.
   PubMedGoogle Scholar
• WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et al.: A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35\(Supp1.1):22–28.
   Google Scholar
• HUSKISSON EC, GHOZLAN R, KURTHEN R, DEGNER FL, BLUHMKI E: A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br. Rheumatol. (1996) 35\(Supp1.1):29–34.
   Google Scholar
• FOELDVARI I, BURGOS-VARGAS R, THON A, TUERCK D: High response rate in the Phase I/II study of meloxicam in juvenile rheumatoid arthritis. j. Rheumatol. (2002) 29:1079–1083.
   PubMed Web of Science ®Google Scholar
• HUSKISSON EC, NARJES H, BLUHMKI E: Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30, and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scan. I Rheumatol. (1994) (Supp1.98). Abstract: 115.
   Google Scholar
• REGINSTER JY, DISTEL M, BLUHMKI E: A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br. Rheumatol. (1996) 35\(Supp1.1):17–21.
   Google Scholar
• FURST D, KOLBA K, FLEISCHMANN R et al.: Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double-blind, dose response study versus placebo and diclophenac. Rheumatol. (2002) 29:436–446.
   Google Scholar
• FLEISCHMANN R, ROSZKO 0, HALL D. How important if flare in the design of NSAID trials in the treatment of rheumatoid arthritis (PA)? Journal of Rheumatology (2001) 28\(Suppl. 63). Abstract: W129.
   Google Scholar
• DOUGADOS M, GUEGUEN A, NAKACHE J-P et al.: Ankylosing Spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatalogy (1999) 38:235–244.
   PubMed Web of Science ®Google Scholar
• AUVINET B, ZILLER R, APPELBOOM T, VELICITAT P: Comparison of the onset and intensity of action of intramuscular meloxicam in patients with acute sciatica. Clin. Titer. (1995) 17:1078–1090.
   Google Scholar
• COLBERG K, HETTICH M, SIGMUND R, DEGNER FL: The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Carr. Med. Res. Opin. (1996) 13:363–353.
   PubMed Web of Science ®Google Scholar
• BOSCH HC, SIGMUND R, HETTISH M: Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Carr. Med. Res. Opin. (1997) 14:29–38.
   PubMed Web of Science ®Google Scholar
• DRESER R-L, LE PARC JM, VELICITAT P, LLEU PL: Oral meloxicam is effective in acute sciatica: two randomized, double- blind trials versus placebo or diclofenac. In/lam. Res (2001) 50\(Supp1.1):S17–S23.
   Google Scholar
• VIDAL L, KNEER W, BATURONE M, SIGMUND R: Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder. In/lam. Res (2001) 50\(Supp1.1):S24–S29.
   Google Scholar
• DISTEL M, MUELLER C, BLUHMKI E, FRIES J: Safety of meloxicam: a global analysis of clinical trials. &J. Rheumatol. (1996) 35\(Supp1.1):68–77.
   Google Scholar
• SCHOENFELD P: Gastrointestinal safetyprofile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med (1999) 107(6A):485-54S.
   Google Scholar
• CHANG D-M, YIUNG T-H, HSU C-T, KUO S-Y, HSIEH T-C: Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin. Rheumatol. (2001) 20:104–113.
   PubMedGoogle Scholar
• PATOIA I, SANTUCCI L, FURNO P et al.: A 4-week double-blind, parallel group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. &J. Rheumatol. (1996) 35\(Supp1.1):61–67.
   Google Scholar
• LIPSCOMB GR, WALLIS N, ARMSTRONG G, REES WDW: Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. &J. Clin. (1998) 46:133–137.
   Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl. I Med. 2000 Nov. 23; 343:1520–1528.
   Google Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13; 284(10):1247–1255.
   Google Scholar
• STICHTENOTH DO, WAGNER B, FROLICH JC: Effect of selective inhibition of the inducible cyclo-oxygenase on rennin release in health volunteers. J. Invest. Med (1998) 46:290–296.
   PubMed Web of Science ®Google Scholar
• BEVIS PJR, BIRD HA, LAPHAM G: An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br. j Rheumatal (1996) 35\(Supp1.1):55–60.
   Google Scholar
• DEGNER FM SIGMUND R, ZEIDLER H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Cm. Titer. (2000) 22:400–410.
   Google Scholar
• MARTIN RM, BISWAS P, MANN RD: The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br. I Clin. Pharmacy]. (2000) 50:35–42.
   PubMed Web of Science ®Google Scholar
• BARNER A. Review of clinical trials andbenefits/risk ratio of meloxicam. Scand. Rheumatal. (1996) 25\(Supp1.102):29–37.
   Google Scholar